Drugs to combat a range of diseases including Alzheimer's, diabetes and cancer. (File photo)
SINGAPORE: Singapore eDevelopment Ltd (SeD), through its subsidiary Global BioLife Inc, has started advanced research on a new universal therapeutic drug platform known as Linebacker, to battle a range of diseases including Alzheimer's, diabetes and cancer. The research will be led by two-time Nobel Prize nominee Daryl Thompson.
SeD said that Thompson would leverage his skills in organic and carbohydrate chemistry and the use of pandemic technology in fighting the Ebola virus in the development of Linebacker. Unlike traditional approaches to curing individual diseases with specific drugs, the Linebacker platform seeks a breakthrough option for multiple diseases to be cured. It can also potentially fight drug-resistant viruses and antibiotic-resistant bacteria.
Thompson was chosen for a Nobel Prize in 2015 and 2016 for his research in cutting-edge organic and carbohydrate chemistry as well his research in pandemics technology to fight pandemics such as Ebola. He has used his skill to start research regarding universal therapeutics to cure the world's deadliest diseases. Scott Truesdell, research coordinator and special projects leader at Global BioLife, will perform the research on the Linebacker platform.
Global BioLife has involved Charles River Laboratories International Inc, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.
"We expect to get validating laboratory data from the universal therapeutic drug platform within the first six months and are targeting for the platform itself to be done within twelve months. We have a unique patented technology and are already getting interested from Big Pharma players and venture capitalists. This interest will rise as the validating data becomes available," said Thompson.
"Global BioLife recognises the need for affordable cures to emerging pandemics and we will leverage the team's deep expertise to develop this new universal therapeutic drug platform," said Dr Tang Peihong, director and CEO of Global BioLife.
© Worldofchemicals News